Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Amgen Inc

AMGN

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Last trade $458.34
Day change -$3.98 (-0.86%)
Day range $455.24 – $464.24
Volume 833,928
Market cap $250.07B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$250.07B
Price / earnings
26.63×
Price / book
17.42×
Price / sales
6.43×
EV / sales
7.48×
EV / EBITDA
17.02×

Profitability

Earnings per share
$17.36
Return on assets
9.78%
Return on equity
65.43%
Dividend yield
2.15%

Liquidity and leverage

Debt / equity
3.76×
Current ratio
1.48×
Quick ratio
1.2×
Cash ratio
0.57×

Cash flow

Price / cash flow
20.78×
Price / free cash flow
26.1×
Free cash flow
$9.58B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for AMGN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$10.37B$10.05B$8.62B$9.87B$9.56B$9.18B$8.15B$9.09B
Cost of revenue$2.79B$2.81B$2.74B$2.98B$3.08B$3.01B$2.97B$3.11B
Gross profit$7.58B$7.24B$5.87B$6.89B$6.48B$6.17B$5.18B$5.97B
Selling, general and administrative$1.68B$1.75B$1.6B$1.95B$1.72B$1.69B$1.69B$1.88B
Research and development$2.11B$1.87B$1.72B$2.14B$1.9B$1.74B$1.49B$1.72B
Total operating expenses$3.87B$3.73B$3.21B$4.17B$3.95B$3.51B$4B$3.66B
Operating income$3.71B$3.51B$2.67B$2.72B$2.53B$2.66B$1.18B$2.31B
Interest expense-$653M-$673M-$657M-$653M-$685M-$694M-$723M-$747M
Income before taxes$4.69B$2.77B$2.08B$1.51B$3.92B$1.57B$1.97B$782M
Income taxes$822M$393M$265M$181M$705M$136M$243M$155M
Net income$3.86B$2.38B$1.82B$1.33B$3.22B$1.43B$1.73B$627M
Net income attributable to common shareholders$3.86B$2.38B$1.82B$1.33B$3.22B$1.43B$1.73B$627M
EBITDA$4.83B$4.63B$3.78B$3.85B$3.83B$4B$2.57B$3.71B
Basic earnings per share$7.14$4.40$3.37$2.48$5.98$2.66$3.22$1.17
Diluted earnings per share$7.08$4.37$3.34$2.45$5.93$2.65$3.20$1.15

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035

The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.

Zacks Investment Research

Should You Invest in the VanEck Biotech ETF (BBH)?

The VanEck Biotech ETF (BBH) is a passively managed fund tracking the MVIS US Listed Biotech 25 Index with $521.91 million in assets and a low 0.35% expense ratio. The fund has delivered strong year-to-date returns of 31.47% but carries higher risk with a beta of 0.70 and concentrated exposure through its top 10 holdings representing 73.82% of assets. BBH holds a Zacks ETF Rank of 2 (Buy), though investors should consider alternatives like XBI and IBB.

Zacks Investment Research

AstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug Klygefa

AstraZeneca received FDA and EU regulatory approvals for Klygefa (gefurulimab), a complement C5 inhibitor for treating adults with AChR-positive generalized myasthenia gravis. The once-weekly, self-administered subcutaneous therapy showed significant improvements in daily activities versus placebo in Phase III trials. While the convenient dosing offers differentiation from AstraZeneca's existing IV therapies (Soliris and Ultomiris), Klygefa faces cannibalization risks and competition from other complement C5 inhibitors and alternative mechanism drugs.

GlobeNewswire Inc.

Anti-Obesity Drugs Market Companies Analysis 2027: Eli Lilly and Novo Nordisk Lead as Pfizer, Roche and Amgen Invest Billions to Challenge Them in a Market Headed for USD 64.96 Billion by 2035

The global anti-obesity drugs market is valued at USD 8.96 billion in 2026 and projected to reach USD 64.96 billion by 2035 at a 24.71% CAGR. Eli Lilly and Novo Nordisk dominate with strong Q3 2026 results, while Pfizer, Roche, and Amgen are investing billions to compete. Key trends include oral GLP-1 formulations, higher efficacy rates (>20% weight loss), and significant manufacturing capacity investments.

The Motley Fool

Which Healthcare ETF Is the Better Buy: State Street’s Pharma Fund XPH or iShares’ Biotech Fund IBB?

The article compares two healthcare ETFs: State Street's XPH (Pharmaceuticals) and iShares' IBB (Biotechnology). XPH charges lower fees (0.35% vs 0.44%), offers higher dividend yield (0.4% vs 0.2%), and focuses on smaller pharmaceutical companies that are acquisition targets. IBB is significantly larger with $11.3B in assets under management and holds 243 established biotech firms. The analyst recommends XPH for long-term investors due to the pharmaceutical industry's active M&A activity and smaller companies' takeover potential.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily
Declared upcoming dividend $2.52 per share
Declared
Oct 27, 2026
Ex-dividend
Nov 20, 2026
Pay date
Dec 11, 2026
Ex-dividendAmount / sharePay dateType
Aug 21, 2026$2.52Sep 11, 2026recurring
May 15, 2026$2.52Jun 5, 2026recurring
Feb 13, 2026$2.52Mar 6, 2026recurring
Nov 21, 2025$2.38Dec 12, 2025recurring
Aug 22, 2025$2.38Sep 12, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.